QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Inflammation & Neurodegenerative Disease Models

Executive Summary: QNZ (EVP4593) is a nanomolar inhibitor of the NF-κB signaling pathway, with an IC50 of 11 nM in human Jurkat T cells and 7 nM for TNF-α production inhibition, as established by luciferase reporter assays and cytokine quantification (APExBIO). The compound's anti-inflammatory effects are validated in a rat carrageenin-induced paw edema model, where QNZ significantly attenuates edema formation (Prostigmin.com). QNZ demonstrates neuroprotective benefits in Drosophila Huntington’s disease (HD) models, slowing motor decline without toxicity at relevant concentrations. It is insoluble in water but achieves solubility in DMSO and ethanol with specific preparation protocols. QNZ is widely used as a research tool in NF-κB pathway modulation, inflammation, and neurodegenerative disease applications (Annexin-V-Cy5.com).

Biological Rationale

The NF-κB pathway regulates genes involved in inflammation, immune responses, and cell survival. Dysregulation of NF-κB is implicated in chronic inflammatory diseases and neurodegenerative disorders, including Huntington’s disease (HD) (Wiggins & Rajapakse 2009, DOI). Traditional treatments for inflammatory diseases, such as 5-aminosalicylates, target downstream effects but may lack specificity for NF-κB transcriptional activation. Small-molecule inhibitors like QNZ (EVP4593) offer direct, potent, and selective inhibition of NF-κB signaling, enabling mechanistic studies and therapeutic exploration. QNZ is a quinazoline derivative designed to suppress NF-κB-driven transcription and cytokine production, addressing the need for precise pathway modulation in cellular and animal models.

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) acts by directly inhibiting activation of the NF-κB pathway. It blocks NF-κB transcriptional activity in stimulated cells, as shown in luciferase reporter gene assays using human Jurkat T cells. QNZ prevents PMA/PHA-induced NF-κB activation and reduces TNF-α production, with IC50 values of 11 nM and 7 nM, respectively (APExBIO). The compound interferes with upstream signaling events leading to IκBα phosphorylation and subsequent NF-κB nuclear translocation. In neuronal models, QNZ at 300 nM reduces store-operated calcium entry (SOC), a process associated with neurodegenerative pathologies (Prostigmin.com). These actions cumulatively attenuate inflammatory and neurodegenerative cascades.

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB transcriptional activation in human Jurkat T cells with an IC50 of 11 nM, measured via luciferase reporter assay (APExBIO).
• It suppresses PMA/PHA-induced TNF-α production at an IC50 of 7 nM, confirming potent anti-inflammatory activity in vitro (Prostigmin.com).
• In vivo, QNZ reduces edema formation in a rat carrageenin-induced paw edema model, demonstrating efficacy as an anti-inflammatory compound (Prostigmin.com).
• In Drosophila transgenic models of Huntington’s disease, QNZ slows progressive motor decline without inducing toxicity, supporting its neuroprotective potential (Annexin-V-Cy5.com).
• QNZ is insoluble in water but dissolves in ethanol (≥10.06 mg/mL, ultrasonic assistance) and DMSO (≥15.05 mg/mL), and is stable when stored at -20°C as a solid (APExBIO).
• Standard working concentrations in neuronal SOC assays are 300 nM, with warming and ultrasonic shaking recommended for stock preparation (Prostigmin.com).
• QNZ is not suitable for long-term storage in solution; fresh preparation is advised to maintain activity (APExBIO).

For extended benchmarks and troubleshooting, see Precision NF-κB Inhibition, which provides advanced workflow advice not covered here.

Applications, Limits & Misconceptions

QNZ (EVP4593) is primarily used in basic and translational research to dissect the role of NF-κB in inflammation, immunity, and neurodegeneration. It is a preferred tool for modeling acute and chronic inflammatory responses, screening of anti-inflammatory compounds, and studying neuronal injury mechanisms such as those in Huntington’s disease (Annexin-V-Cy5.com). Unlike broad-spectrum anti-inflammatories, QNZ offers pathway-specific inhibition, reducing off-target effects in mechanistic studies. Researchers should note that QNZ’s effects are context-dependent and may vary with cell type, stimulus, and experimental design. This article extends the fundamental mechanism reviews in Potent Quinazoline NF-κB Inhibitor for Inflammation by providing detailed application-specific guidance and cautionary notes.

Common Pitfalls or Misconceptions

• QNZ is not water-soluble: Attempting to dissolve QNZ (EVP4593) in aqueous buffers leads to incomplete solubilization and unreliable dosing (APExBIO).
• Not a direct anti-infective: QNZ does not possess direct antimicrobial or antiviral properties; its effects are via NF-κB modulation only.
• Species and Cell-Type Specificity: Efficacy and cytotoxicity can vary widely between species and cell types; always perform preliminary titration experiments.
• No sustained activity when pre-diluted: QNZ solutions degrade over time; long-term storage in solution form reduces potency and is not recommended.
• Not a 5-ASA analog: QNZ is chemically and mechanistically distinct from 5-aminosalicylate drugs like balsalazide (Wiggins & Rajapakse 2009, DOI).

For a discussion of how QNZ benchmarks against other NF-κB inhibitors and is integrated into advanced disease models, refer to this workflow-focused review, which complements the present article by emphasizing scalability and troubleshooting in complex systems.

Workflow Integration & Parameters

QNZ (EVP4593) is supplied as a crystalline solid by APExBIO. The recommended solvents are DMSO (minimum 15.05 mg/mL) and ethanol (minimum 10.06 mg/mL with ultrasonic assistance). Dissolution is enhanced by warming to 37°C and sonication. Stock solutions should be prepared fresh, aliquoted, and stored at -20°C for no more than several weeks. For cell-based assays, working concentrations typically range from 10 nM to 1 μM, with 300 nM commonly used in neuronal SOC studies. Prior to use, ensure full dissolution and avoid repeated freeze-thaw cycles. QNZ is incompatible with aqueous stock storage; always dilute into media immediately before use. For animal studies, consult institutional guidelines for dosing and vehicle compatibility.

Conclusion & Outlook

QNZ (EVP4593) stands as a reference NF-κB inhibitor, distinguished by its nanomolar potency, defined mechanism, and consistent performance in preclinical inflammation and neurodegeneration models. Its selective targeting of NF-κB transcriptional activation enables precise dissection of inflammatory pathways while minimizing off-target effects. As research progresses, QNZ is expected to remain a critical tool in pathway modulation studies and disease modeling. For product specifications and ordering, visit the QNZ (EVP4593) product page (A4217).